**Specifications Table**TableSubject area*Clinical research; meta-analysis*More specific subject area*Medicine; Cardiology; Reperfusion injury*Type of data*Figure*How data was acquired*Meta-analysis*Data format*Analyzed*Experimental factors*Ciclosporin or nicorandil, exclusion of metoprolol and follow-up length for reperfusion in ST elevation myocardial elevation treated with primary coronary intervention.*Experimental features*15 studies focused on drugs targeting mitochondrial function vs. placebo in patients undergoing primary PCI for STEMI, of which 3 with cyclosporine, 2 with nicorandil, only one study with metoprolol were retrieved from MEDLINE, Cochrane Library, Google Scholar and Biomed Central*Data source location*Italy, USA, Israel, Japan, Denmark, UK, France, Norway, Spain.*Data accessibility*Data is with this article*

**Value of the data**•The use of cyclosporine or nicorandil at the time of primary percutaneous coronary angioplasty (PCI) on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes, show the absence of any potential benefit.•Excluding a trial on metoprolol [@bib12], which has a complex mechanism of action, not targeting only mitochondrial function, the pooled analysis on fatal and non fatal outcomes of the 14 studies did not changed.•The analysis on follow-up length shows effects on hospital readmission for HF for trials with longer follow-up.•These additional analyses should be the basis to plan further randomized clinical trials (RCTs) on reperfusion injury in ST elevation myocardial infarction (STEMI) patients undergoing PCI, focusing attention on other molecular mitochondrial targets.•New RCTs on reperfusion injury should have a longer follow-up analysis.

1. Data {#s0005}
=======

Considering only trial focused on cyclosporine versus placebo, the HR for CV mortality, all-cause mortality and hospital readmission for HF were not statistical significant (*p*=0.33; *p*=0.16; *p*=0.95, respectively) ([Fig. 1](#f0005){ref-type="fig"}). The same data are obtained considering only trials on nicorandil (*p*=0.06 for CV mortality; *p*=0.07 for all-cause death; *p*=0.2 for hospital readmission for HF) ([Fig. 2](#f0010){ref-type="fig"}). After the exclusion of the study on metoprolol from pooled analysis on trials with indirect/unspecific mechanism of action against mitochondrial component/pathway, the HR for CV death, all-cause death and hospital readmission for HF were significantly reduced (*p*=0.03; *p*=0.008; *p*=0.0001, respectively) ([Fig. 3](#f0015){ref-type="fig"}). Finally, the analysis on follow-up on all the studies included in the meta-analysis showed a reduction in hospital readmission for HF in studies with follow-up length ≥12 months (HR 0.46; 95% CI 0.45--0.92, *p*=0.03) ([Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}).Fig. 1Forest plots on cardiovascular mortality, all-cause mortality and hospital readmission for HF in studies randomizing to cyclosporine vs. placebo. CV: cardiovascular.Fig. 1Fig. 2Forest plots on cardiovascular mortality, all-cause mortality and hospital readmission for HF in studies randomizing to nicorandil vs. placebo. CV: cardiovascular.Fig. 2Fig. 3Forest plots on cardiovascular mortality, all-cause mortality and hospital readmission for HF in studies randomizing indirect/unspecific mechanism of action against mitochondrial component/pathway vs. placebo, excluding the study on metoprolol [@bib12]. ANP: atrial natriuretic peptide. NIC: nicorandil. CV: cardiovascular. HF: heart failure. hosp: hospitalization.Fig. 3Fig. 4Forest plot on cardiovascular mortality after stratification of studies according to follow-up length. SP: safety population. ANT: anterior cohort. INF: inferior cohort. ANP: atrial natriuretic peptide. NIC: nicorandil. CV: cardiovascular.Fig. 4Fig. 5Forest plot on all-cause mortality after stratification of studies according follow-up length. SP: safety population. ANT: anterior cohort. INF: inferior cohort. ANP: atrial natriuretic peptide. NIC: nicorandil.Fig. 5Fig. 6Forest plot on hospital readmission for heart failure after stratification of studies according follow-up length. SP: safety population. ANT: anterior cohort. INF: inferior cohort. ANP: atrial natriuretic peptide. NIC: nicorandil. HF: heart failure.Fig. 6

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Search strategy {#s0015}
--------------------

A systematic review and meta-analysis was performed following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) criteria [@bib18], [@bib19], [@bib20], [@bib21]. The protocol of this study was published on PROSPERO (CRD42016033085).

Papers were retrieved in MEDLINE, Cochrane Library, Google Scholar and Biomed Central. The terms searched were: (reperfusion injury) AND ((PCI) OR (percutaneous coronary intervention) OR (ST elevation myocardial infarction) OR (STEMI) OR (myocardial infarction)) [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16].

2.2. Selection criteria {#s0020}
-----------------------

Detailed description of selection criteria of the papers is described elsewhere [@bib17]. In particular, we focused on i) RCTs ii) enrolling STEMI patients; with iii) reperfusion strategy by primary PCI; iv) comparison of agent/drug against RI vs. placebo/gold standard treatment.

2.3. Data abstraction, endpoints, contact with authors {#s0025}
------------------------------------------------------

We performed a pre-hoc stratification of studies according to mechanism of action targeting a mitochondrial component/pathway (direct/selective vs. indirect/unspecific) according to a recent overview [@bib22]. The analyses were performed according to the following criteria: i) administration of cyclosporine, ii) administration of nicorandil, iii) follow-up length \<12 vs. ≥12 months iv) indirect/unspecific drugs after exclusion of the study of Pizarro et al. [@bib12]. The primary endpoint of the analysis was the incidence of cardiovascular death. Secondary endpoints were: all-cause death, hospital readmission for heart failure (HF).

2.4. Data analysis and synthesis {#s0030}
--------------------------------

The endpoints were expressed as odds ratio (OR). Point estimates and standard errors were calculated and combined by the generic inverse variance method [@bib23], computing risk estimates with 95% confidence intervals according to logarithmic transformation of the OR. A random effect model was used. Statistical heterogeneity was assessed with the Cochran\'s Q test and the I^2^ statistic [@bib24]. To test the difference between sub-group analyses the Chi^2^ test has been used. Prometa (Internovi, Cesena, Italy) and RevMan 5 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) software were used for statistical analyses.
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